10 MORE mistakes medtech startups make  — and how to avoid them 

In our previous article, we explored ten common mistakes medtech startups make while developing and commercializing a medical device. This article continues that conversation with mistakes 11 through 20—additional challenges that can create avoidable delays, costs and barriers to adoption. 

Bringing a medical device to market requires much more than a strong product and a clear clinical need. Medtech startups must navigate purchasing decisions, intellectual property, regulatory strategy, manufacturing, quality systems, commercialization and financing—all while trying to preserve time, capital and momentum. 

Many of the mistakes startups make are not caused by a lack of commitment or technical expertise. More often, they happen because teams make reasonable decisions too early, before they fully understand how those decisions will affect adoption, scale and long-term value. 

At Avio Medtech, we see recurring patterns across the startup ecosystem. The following ten (MORE) mistakes are additional examples of where early planning and practical guidance can help companies avoid expensive detours. 

11. Confusing physician enthusiasm with purchasing intent 

Physician enthusiasm is an important early signal. If clinicians do not recognize the value of a product or believe it will improve patient care, the company should take a closer look at its underlying assumptions. 

But enthusiasm alone does not guarantee adoption. 

A physician may love a product and lack the authority to purchase it. The final decision may involve hospital administration, a value analysis committee, procurement, finance, a practice group or a payer. In some cases, the physician is not even an employee of the organization responsible for buying the product. 

Before assuming that clinical interest equals market demand, map the entire purchasing process: 

• Who uses the product? 

• Who influences the decision? 

• Who controls the budget? 

• Who approves new technology? 

• What evidence does each stakeholder require? 

Understanding those dynamics early can influence product design, regulatory claims, evidence generation, pricing, financing and go-to-market strategy. In medtech, the goal is not simply to create a product that physicians want. It is to create a product the entire purchasing system can adopt. 

12. Treating IP as a filing instead of a strategy 

Most medtech founders understand that intellectual property matters. The problem is that many companies approach IP as a one-time patent filing rather than as an evolving business strategy. 

A strong IP strategy should consider where the company and technology may be several years from now. That includes questions such as: 

• How could the technology expand into new indications or applications? 

• Which aspects of the product are most valuable to protect? 

• Should the company pursue multiple patents? 

• When should international protection be considered? 

• How will future filings affect the company’s budget and timeline? 

• What will an acquirer or strategic partner expect to see? 

The objective is not to predict every future development. It is to avoid building a narrow IP position that limits the company’s options later. 

Early strategic thinking can help reduce unnecessary costs, preserve flexibility and increase the value of the business during future financing, licensing, partnership, or acquisition discussions. Filing a patent may protect an invention. Building an IP strategy helps protect the company’s future. 

13. Building the business before validating the regulatory pathway 

Regulatory strategy should be established before a company becomes deeply committed to product design, testing, evidence generation, and commercial claims. 

There may be several possible routes to market, including 510(k), De Novo, PMA, or an exempt pathway. The appropriate route depends on the product, its intended use, its risk profile, its claims, and the evidence needed to support market adoption. Pro tip: check out our article on FDA pathways, simplified for more guidance. 

A common mistake is to choose a pathway based only on which option appears fastest or least expensive. That may reduce upfront costs but create additional expenses later if the company must conduct new studies, repeat testing, redesign the product or pursue a second submission to support broader claims. 

A more useful question is: What does the market need to believe, and what regulatory pathway will generate the evidence to support that belief? 

Start by defining the product’s intended claims and target market. Then work backward to determine the evidence required and the most appropriate regulatory strategy. The simplest pathway on paper is not always the most efficient path to commercial value. 

14. Defaulting to 510(k) without evaluating the alternatives 

The 510(k) pathway is familiar to many medtech companies, but familiarity should not turn into an automatic decision. 

For some products, a 510(k) may be the right path. For others, De Novo or another pathway may better support the company’s market, technology, and long-term strategy. A De Novo submission may require more evidence than a traditional 510(k), but it can also help establish a new classification and define the expectations for future products in the category. 

That additional evidence may become a commercial asset. Data developed for regulatory purposes can also help the sales team communicate value to clinicians, hospitals, investors and strategic partners. 

The goal is not simply to obtain authorization to sell. The goal is to select the regulatory pathway that best supports adoption, creates a defensible market position and produces value for patients and the business. 

15. Designing a prototype instead of designing for manufacturing 

A prototype demonstrates that something can work. A commercial product must also be practical, repeatable, cost-effective and scalable to manufacture. 

Startups do not need to build a fully optimized, high-volume production line on day one. However, they should begin thinking early about how the product will transition from prototype manufacturing to pilot production and, eventually, commercial scale. 

Early design decisions can have a major impact on: 

• Assembly time 

• Material costs 

• Rework and waste 

• Quality control 

• Supplier requirements 

• Production yield 

• Automation potential 

• Manufacturing lead times 

Products that are overly complex or dependent on extensive manual work may be manageable at low volumes but become difficult and expensive to produce as demand increases. 

Design for manufacturing is not about solving every future production problem immediately. It is about identifying the transitions ahead and making decisions today that will make those transitions easier. 

16. Treating clearance or approval as the finish line 

Obtaining FDA clearance or approval is a major milestone, but it is not the end of the work. It is the point at which the company enters a new operating environment. 

Once a product is on the market, the company must be prepared to manage customer feedback, complaints, manufacturing changes, supplier issues, quality events and other post-market responsibilities. Production may also become more complex as the company moves from one unit to ten, one hundred or one thousand. 

Without the right infrastructure, a single complaint or manufacturing problem can consume the team’s attention and disrupt commercial growth. 

Before launch, startups should ensure they have: 

• A functioning quality management system 

• Clear procedures for complaint handling 

• Defined processes for feedback and corrective action 

• Appropriate supplier and manufacturing oversight 

• Team members who understand their post-market responsibilities 

• A process for identifying and responding to recurring issues 

Commercial growth is only valuable if the company can support its customers and maintain control of product quality as volume increases. 

17. Waiting until clearance to begin commercialization 

Pre-market companies cannot sell or commercially promote a product before they are legally permitted to do so. But that does not mean they must wait until clearance or approval to prepare the market. 

There are many activities startups can begin early, including: 

• Building relationships with key opinion leaders 

• Learning how target customers make purchasing decisions 

• Testing the economic narrative 

• Mapping potential distributors and sales partners 

• Attending relevant medical meetings 

• Conducting appropriate customer discovery and focus groups 

• Developing training and support materials 

• Identifying early adopter sites 

The objective is to build understanding and readiness without making impermissible promotional claims. 

For resource-constrained startups, this work may initially depend on the founders. That can be challenging, but starting early helps prevent a common and costly scenario: obtaining clearance and then spending the next six to twelve months building the commercial infrastructure while the company continues to burn cash. 

You can also consider fractional sales leaders, like those in our Navigator Network. You get the best of both worlds: expertise without cash burnout. 

The launch date should not be the first day the company begins thinking about how to sell. 

18. Running pilots without a path to conversion 

Clinical and commercial pilots can provide valuable real-world feedback. They can help a company refine its product, demonstrate value, generate evidence and build customer relationships. 

But a pilot does not automatically become a commercial account. 

Startups should discuss the path beyond the pilot before the pilot begins. That may include: 

• Defining the commercial terms that would apply after the pilot 

• Establishing success criteria 

• Agreeing on what happens if those criteria are met 

• Identifying the customer’s purchasing process 

• Determining whether the product is treated as capital equipment, a supply or another budget category 

• Understanding value analysis, contracting, stocking and approval requirements 

Pilot agreements should create a bridge to adoption wherever possible. If the company waits until the pilot is complete to discuss pricing, purchasing or next steps, the customer may have little incentive to move quickly—or to pay more than the pilot rate. 

A successful pilot should answer more than “Does the product work?” It should also help answer “What would it take for this organization to buy it?” 

19. Underestimating the full cost of reaching adoption 

Many startups prepare an initial budget based on product development, testing, regulatory work and perhaps a clinical study. The challenge is that market adoption often requires considerably more than simply developing a product and obtaining authorization. 

The full cost may include: 

• Product development and redesign 

• Bench and laboratory testing 

• Clinical evidence 

• Regulatory consulting and submission fees 

• Quality systems and audits 

• Intellectual property and legal work 

• Manufacturing scale-up 

• Inventory and working capital 

• Sales and marketing 

• Customer training and support 

• Health economics and reimbursement evidence 

• Unplanned testing or retesting 

A device that is technically ready for market may still need additional evidence before clinicians, hospitals or payers are willing to adopt it. 

The most realistic financial models include contingency for both predictable work and unexpected setbacks. Founders who have not previously taken a device from concept through commercialization should seek input from people who have. Their experience can help identify hidden costs, realistic timelines and common failure points. 

A credible plan does not eliminate surprises. It reduces the number and severity of them. 

20. Assuming the U.S. and European markets are interchangeable 

Companies planning to enter both the United States and Europe sometimes assume that the regulatory work completed for one market will transfer easily to the other. 

Although there are areas of alignment, the FDA and European Union regulatory systems are not identical. They may involve different requirements, standards, risk considerations, clinical expectations, quality processes and documentation. 

Waiting until after completing one market’s work to consider the second can create avoidable delays and duplicated effort. If international expansion is part of the company’s strategy, the team should evaluate both markets early. 

That does not necessarily mean pursuing every market at the same time. It means understanding the requirements early enough to identify opportunities for alignment. In some cases, a modest change to testing, documentation or design controls can make a later market entry more efficient. 

International strategy should be part of early planning—not an afterthought once the first market is complete. 

The common thread: plan before the options narrow 

These mistakes span clinical validation, IP, regulation, manufacturing, quality, commercialization and finance. What connects them is timing. 

The further a company advances without examining its assumptions, the more expensive it becomes to change direction. A decision made during concept development may be relatively easy to adjust. The same decision made after design freeze, testing, regulatory submission or commercial launch can require significant time and capital to correct. 

The strongest medtech teams do not assume they will avoid every mistake. Instead, they pressure-test their plans early, seek input from people with relevant experience and connect decisions across functions. 

Market adoption, regulatory strategy, evidence generation, manufacturing, quality and commercialization should not operate as isolated workstreams. They are interdependent parts of the same business plan. 

The goal is not simply to get a product on the market. It is to build a product and business that customers can adopt, the organization can support and investors can believe in. 

At Avio Medtech, we help medtech companies connect those pieces, identify risks earlier, and build practical strategies for moving from concept to commercialization. Reach out to learn how we can help your team avoid costly missteps and move forward with greater confidence. 

FAQ 

What is the biggest mistake medtech startups make? 

One of the most common mistakes is confusing interest from a small group of clinicians with broad market demand. Physician input is essential, but startups must also understand the administrative, financial, procurement and reimbursement stakeholders involved in purchasing. 

When should a medtech startup begin commercialization planning? 

Commercialization planning should begin well before regulatory clearance or approval. While companies cannot sell or make unauthorized promotional claims before they are permitted to do so, they can build relationships, understand purchasing processes, prepare their commercial infrastructure and develop a launch strategy. 

Why should medtech startups think about manufacturing early? 

Design decisions made during prototyping can affect cost, quality, production yield and scalability. Early design-for-manufacturing planning helps reduce the risk of creating a product that works technically but is difficult or expensive to produce at commercial volumes. 

How can a startup improve pilot-to-customer conversion? 

Discuss the transition to commercial terms before the pilot begins. Define success criteria, understand the customer’s purchasing process and agree on what happens if the product demonstrates the expected value. 

Should every medtech startup pursue a 510(k)? 

No. A 510(k) may be appropriate for some products, but startups should evaluate all relevant regulatory pathways based on their intended claims, evidence requirements, market needs, and long-term business strategy. The best pathway is the one that supports adoption and value creation—not necessarily the one that appears simplest at the outset.